The archives

SCIENCE HAD ITS ‘CHRONIC PAIN REVOLUTION.’ SO WHY IS TREATMENT STILL BROKEN, DELAYED AND OUT OF REACH?

A war surgeon’s struggles David Nott has spent ...

SPECIAL REPORT

CITY

In rude health: AstraZeneca, Britain’s biggest drugmaker, has “risen to the challenge” of US healthcare providers negotiating drug prices by posting “solid first-half sales growth”, says Derren Nathan

For a long time we’ve been focusing on dopamine detoxes, but do we need more, not less, of the d-word? And could a lack be the real culprit behind treatment-resistant depression, asks Emma Green